GP6 and acute lung injury: Beyond thrombosis, GPVI drives thrombo-inflammatory complications in multiple disease settings, such as myocardial12 and cerebral I/R injury,5–8,13 acute lung injury,10 or glomerulonephritis54 and, thus, GPVI inhibition by EMA601 might impose beneficial effects on a broad range of disorders, that are not yet efficiently addressed by existing drugs.